![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Medigene AG: Medigene Signs Exclusive License Agreement with Leiden University to Develop Novel T...
Medigene AG announced that it has entered into an exclusive license agreement with Leiden University...
RetiPharma Secures Funding to Develop Treatments of Degenerative Eye Disorders
RetiPharma, focusing on the development of products for the treatment of degenerative eye disorders based...
Sygnature Discovery announces multi target drug discovery deal with Sitryx Therapeutics
Sygnature Discovery, a leading independent integrated drug discovery and pre-clinical services company, has announced a...
Proprietary Nasal Delivery Formulation of Diazepam Developed by Particle Sciences’ Reaches NDA
Proprietary nasal delivery formulation of diazepam for the treatment of epilepsy developed by CDMO, Particle...
Celerion Expands NASH Biomarkers Services With the Implementation of FibroScan
Celerion, a leader in early clinical research, is pleased to announce the implementation of FibroScan®...
AbbVie to Assume Full Development and Commercial Control of Cystic Fibrosis Research Program
AbbVie ,a research-based global biopharmaceutical company, announced that it will assume full development and commercial...
Arzeda Leverages Scalable Synthetic Biology Resources to Drive Computational Protein Design Platform
Arzeda, the Protein Design Compan, Twist Bioscience Corporation, TeselaGen Biotechnology Inc. and Labcyte Inc. have...
DSCSA one-month countdown
From 27 November 2018, the Drug Supply Chain Security Act (DSCSA) will be actively enforced...
Collaboration to identify biomarkers that predict therapeutic response
The National Center for Tumor Diseases (NCT) Heidelberg and Protagen AG announced a collaboration to...
Is the market now DSCSA ready?
Roundtable questionsIn November 2017, the pharma industry was granted an extension of the Drug Supply...